AMLX · NASDAQ
Amylyx Pharmaceuticals (AMLX) Stock Price & Fundamentals
Amylyx Pharmaceuticals (AMLX) closed at $411.23 on Oct 9, 2026, up 0.18% from the previous close of $410.51.
Share price, past year
1Y +13.12%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $411.23 |
| Sep 30, 2026 | $410.59 |
| Aug 31, 2026 | $398.26 |
| Jul 31, 2026 | $409.58 |
| Jun 30, 2026 | $425.53 |
| May 29, 2026 | $376.48 |
| Apr 30, 2026 | $360.81 |
| Mar 31, 2026 | $376.81 |
| Feb 27, 2026 | $366.81 |
| Jan 30, 2026 | $371.66 |
| Dec 31, 2025 | $367.12 |
| Nov 28, 2025 | $372.54 |
| Oct 31, 2025 | $372.42 |
Key statistics
- Market cap
- $45.80B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.41
- Revenue (TTM)
- $0.00
- Net income (TTM)
- −$152.09M
- Shares outstanding
- 111.4M
- Dividend yield
- —
- 52-week range
- $347.09 – $427.09
Amylyx Pharmaceuticals's market cap is $45.80B, based on a share price of $411.23 and 111.4M shares outstanding as of Jun 30, 2026.
Financials
Amylyx Pharmaceuticals reported revenue of $0.00 for fiscal 2025, down 100.00% from fiscal 2024.
Amylyx Pharmaceuticals reported a net loss of $144.74M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $0.00 | −100.0% | −$144.74M | — | −$1.53 | −$123.48M |
| FY2024ended Dec 31, 2024 | $87.37M | −77.1% | −$301.74M | −345.4% | −$4.43 | −$167.80M |
| FY2023ended Dec 31, 2023 | $380.79M | +1,612.9% | $49.27M | 12.9% | $0.70 | $10.68M |
| FY2022ended Dec 31, 2022 | $22.23M | +7,700.0% | −$198.38M | −892.4% | −$3.39 | −$182.40M |
| FY2021ended Dec 31, 2021 | $285.00K | — | −$87.93M | −30,853.0% | −$13.35 | −$75.15M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q4 FY2025ended Dec 31, 2025 | $0.00 | −$33.00M | −$0.28 |
| Q3 FY2025ended Sep 30, 2025 | $0.00 | −$34.39M | −$0.37 |
| Q2 FY2025ended Jun 30, 2025 | $0.00 | −$41.44M | −$0.46 |
| Q1 FY2025ended Mar 31, 2025 | $0.00 | −$35.91M | −$0.42 |
| Q3 FY2024ended Sep 30, 2024 | $416.00K | −$72.70M | −$1.07 |
| Q2 FY2024ended Jun 30, 2024 | −$1.02M | — | — |
| Q1 FY2024ended Mar 31, 2024 | $88.64M | — | — |
| Q4 FY2023ended Dec 31, 2023 | $108.45M | — | — |
Company profile
- Name
- Amylyx Pharmaceuticals, Inc.
- Ticker
- AMLX
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 55 Cambridge Parkway, Suite 6w, Cambridge, MA 02142
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001658551
Recent SEC filings
- Sep 8, 2026
- Aug 20, 2026
- Aug 18, 2026
- Aug 18, 2026
- Aug 6, 2026
- Aug 6, 2026
- Jun 4, 2026
- May 7, 2026
Frequently asked questions
What is Amylyx Pharmaceuticals's stock price?
Amylyx Pharmaceuticals (AMLX) closed at $411.23 on Oct 9, 2026, up 0.18% from the previous close of $410.51.
What is Amylyx Pharmaceuticals's market cap?
Amylyx Pharmaceuticals's market cap is $45.80B, based on a share price of $411.23 and 111.4M shares outstanding as of Jun 30, 2026.
How much revenue does Amylyx Pharmaceuticals make?
Amylyx Pharmaceuticals reported revenue of $0.00 for fiscal 2025, down 100.00% from fiscal 2024.
Does Amylyx Pharmaceuticals pay a dividend?
Amylyx Pharmaceuticals's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Amylyx Pharmaceuticals, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures